(Updates shares in paragraph 2, adds conference call comments in paragraphs 10, 14) By Michael Erman and Puyaan Singh Oct 30 (Reuters) – Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from generic competition for several older drugs. Shares of the company were up 3.5% at $44.08. Bristol Myers also raised its full-year revenue forecast, reflecting optimism that its portfolio of recently launched drugs will plug a multibillion-dollar revenue gap from patent expirations that open several best-selling drugs to competition. CEO Christopher Boerner has also aggressively pursued acquisitions and partnerships to fill Bristol Myers' pipeline. For the thi

See Full Page